Raymond James Trust N.A. trimmed its holdings in Amgen, Inc. (NASDAQ:AMGN) by 2.3% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 52,917 shares of the medical research company’s stock after selling 1,228 shares during the period. Raymond James Trust N.A.’s holdings in Amgen were worth $10,053,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of AMGN. Ruggie Capital Group lifted its stake in shares of Amgen by 297.1% in the fourth quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock worth $26,000 after buying an additional 101 shares during the last quarter. Capital Financial Planning LLC acquired a new stake in shares of Amgen in the fourth quarter worth $27,000. Massey Quick Simon & CO. LLC lifted its stake in shares of Amgen by 710.5% in the fourth quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock worth $30,000 after buying an additional 135 shares during the last quarter. Next Capital Management LLC acquired a new stake in shares of Amgen in the fourth quarter worth $33,000. Finally, Essex Investment Management Co. LLC acquired a new stake in shares of Amgen in the fourth quarter worth $39,000. 80.65% of the stock is owned by institutional investors.
In other news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $193.18, for a total value of $386,360.00. Following the completion of the transaction, the director now owns 15,092 shares in the company, valued at approximately $2,915,472.56. The sale was disclosed in a filing with the SEC, which is available at this link. In the last 90 days, insiders sold 6,000 shares of company stock valued at $1,115,580. Corporate insiders own 0.25% of the company’s stock.
A number of brokerages have recently weighed in on AMGN. JPMorgan Chase & Co. restated a “hold” rating and issued a $190.00 price objective on shares of Amgen in a research note on Wednesday. Mizuho set a $208.00 target price on shares of Amgen and gave the company a “buy” rating in a research note on Friday, May 10th. Cowen reiterated a “buy” rating and set a $229.00 target price on shares of Amgen in a research note on Wednesday, May 1st. BidaskClub cut shares of Amgen from a “hold” rating to a “sell” rating in a research note on Tuesday, April 23rd. Finally, Zacks Investment Research cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the company. Amgen has a consensus rating of “Hold” and an average price target of $208.84.
Shares of AMGN stock opened at $169.87 on Thursday. Amgen, Inc. has a 52-week low of $166.30 and a 52-week high of $210.19. The firm has a market capitalization of $102.23 billion, a PE ratio of 11.80, a price-to-earnings-growth ratio of 2.21 and a beta of 1.15. The company has a quick ratio of 2.53, a current ratio of 2.77 and a debt-to-equity ratio of 2.71.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, April 30th. The medical research company reported $3.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.45 by $0.11. Amgen had a net margin of 34.00% and a return on equity of 71.02%. The company had revenue of $5.56 billion during the quarter, compared to analysts’ expectations of $5.55 billion. During the same quarter in the prior year, the company posted $3.47 EPS. The business’s revenue was up .1% on a year-over-year basis. As a group, equities research analysts forecast that Amgen, Inc. will post 13.93 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is 40.28%.
WARNING: This piece was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.thelincolnianonline.com/2019/05/16/raymond-james-trust-n-a-sells-1228-shares-of-amgen-inc-amgn.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Further Reading: Why Invest in Dividend Achievers?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.